Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies.
Kister I, Curtin R, Pei J, Perdomo K, Bacon TE, Voloshyna I, Kim J, Tardio E, Velmurugu Y, Nyovanie S, Valeria Calderon A, Dibba F, Stanzin I, Samanovic MI, Raut P, Raposo C, Priest J, Cabatingan M, Winger RC, Mulligan MJ, Patskovsky Y, Silverman GJ, Krogsgaard M. Kister I, et al. Among authors: curtin r. Ann Clin Transl Neurol. 2022 Oct;9(10):1643-1659. doi: 10.1002/acn3.51664. Epub 2022 Sep 27. Ann Clin Transl Neurol. 2022. PMID: 36165097 Free PMC article.
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
Kister I, Patskovsky Y, Curtin R, Pei J, Perdomo K, Rimler Z, Voloshyna I, Samanovic MI, Cornelius AR, Velmurugu Y, Nyovanie S, Kim JJ, Tardio E, Bacon TE, Zhovtis Ryerson L, Raut P, Pedotti R, Hawker K, Raposo C, Priest J, Cabatingan M, Winger RC, Mulligan MJ, Krogsgaard M, Silverman GJ. Kister I, et al. Among authors: curtin r. Ann Neurol. 2022 Jun;91(6):782-795. doi: 10.1002/ana.26346. Epub 2022 Apr 1. Ann Neurol. 2022. PMID: 35289960 Free PMC article.
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.
Kister I, Curtin R, Piquet AL, Borko T, Pei J, Banbury BL, Bacon TE, Kim A, Tuen M, Velmurugu Y, Nyovanie S, Selva S, Samanovic MI, Mulligan MJ, Patskovsky Y, Priest J, Cabatingan M, Winger RC, Krogsgaard M, Silverman GJ. Kister I, et al. Among authors: curtin r. Ann Clin Transl Neurol. 2024 Jul;11(7):1750-1764. doi: 10.1002/acn3.52081. Epub 2024 May 7. Ann Clin Transl Neurol. 2024. PMID: 38713096 Free PMC article.